Methods of determining health status of cat based on one or more biomarkers and methods of treating risk of death identified by health status
By evaluating the cat's blood biomarker level to calculate phenotypic age, the problem of inability to accurately evaluate cat health status and death risk in the prior art is solved, and accurate prediction and personalized intervention of cat death risk and healthy lifespan are achieved.
Patent Information
- Application Number
- CN202380033085.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-28
- Filing Date
- 2023-04-27
- Publication Date
- 2024-11-22
AI Technical Summary
Existing methods are difficult to accurately assess cat health status and mortality risk, especially the inability to effectively distinguish the differences between biological age and full age, resulting in the inability to identify individuals at risk for age-related disorders early.
By evaluating the cat's blood biomarker level, especially white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, and red blood cell count, the cat's phenotypic age, thus directly predicting the risk of death and the probability of healthy lifespan.
This method can more accurately identify cats' risk of death and probability of healthy lifespan, and provides personalized dietary and lifestyle advice to help extend cats' healthy lifespan.
Smart Images

Figure BDA0005074972820000051 
Figure BDA0005074972820000052 
Figure BDA0005074972820000181
Abstract
Description
Technical Field
[0001] The present invention relates to methods for determining the health status of a cat, in particular the risk of mortality and / or the probability of a longer healthy life span, based on biomarkers. Background Art
[0002] The ability to determine information about a cat's health is desirable to inform the cat's overall health and well-being. For example, the ability to determine information about a cat's overall health may be helpful in assessing whether a cat would benefit from a dietary or supplement-based intervention.
[0003] As is well known, chronological age is a major indicator of overall health status, wherein an increase in chronological age is associated with a decrease in health status. However, depending on genetics, nutrition, and lifestyle, the rate of individual aging may be slower or faster than chronological age. Therefore, chronological age may not always reflect the risk of reduced aging rate or health status of an individual. On the other hand, the biological age of an individual (based on, for example, clinical biochemistry and cell biology measurements) may be different from that of other individuals of the same chronological age. Methods for determining biological age may help to identify individuals at risk of age-related disorders earlier than expected based on the chronological age of the individual (see, for example, WO2019 / 165064).
[0004] However, additional methods are needed to determine information about the health of cats. Summary of the invention
[0005] The present invention relates to a method for quantifying the health status of a cat based on biomarkers, particularly blood biomarkers. The method is capable of determining the mortality risk and / or the probability of healthy life span of a cat by assessing the phenotypic age of the cat.
[0006] Existing methods for assessing the health status of cats using blood biomarkers determine biological age based on a correlation between blood biomarkers and chronological age. Calculating the biological age of an animal may include determining the difference in the level of one or more biomarkers compared to the expected level of the biomarkers given the chronological age. Thus, this method is based on using chronological age as the primary indicator of overall health.
[0007] In contrast, the present invention contemplates the direct predictive value of the biomarkers for the risk of death and / or the probability of healthy life span. For example, a given biomarker may not be directly correlated with chronological age, but may indicate a specific pathological condition, thereby indicating the probability of increased risk of death and / or decreased healthy life span. Thus, the present method can be described as identifying the phenotypic age (PhenoAge) of a cat. Therefore, the biomarkers of the present invention are not necessarily correlated with chronological age, but are related to the difference between the phenotypic age and the chronological age of a cat.
[0008] The present invention provides a method for determining the risk of mortality and / or the probability of healthy life span in a cat; the method comprises determining the level of one or more biomarkers in one or more samples obtained from the cat.
[0009] In one aspect, the present invention provides a method for determining the risk of mortality and / or probability of healthy life span of a cat; the method comprising determining the level of one or more biomarkers in one or more samples obtained from the cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin and / or mean corpuscular hemoglobin concentration.
[0010] The one or more biomarkers may be selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin and / or red blood cell count.
[0011] The inventors have shown that each of these biomarkers individually correlates with phenotypic age and is therefore predictive of mortality risk and / or probability of healthy life span.
[0012] Determining the risk of death can refer to determining the likelihood that a cat will live longer or shorter than, for example, a comparable cat of the same chronological age. Thus, the present method can determine the probability of a cat's healthy life span or healthy lifespan compared to, for example, a comparable cat of the same chronological age. Suitably, the risk of death can be equated to the probability of a cat's healthy lifespan; wherein a decrease in the risk of death is equated to an increased probability of a longer healthy lifespan for a cat, or an increase in the risk of death is equated to a decreased probability of a longer healthy lifespan for a dog. The risk of death can be expressed as the difference between the phenotypic age and the chronological age of a cat (phenotypic age is advanced). For example, an increase in phenotypic age compared to chronological age can indicate an increased risk of death for a cat; and a decrease in phenotypic age compared to chronological age can indicate a decreased risk of death for a cat.
[0013] In one embodiment, the method may include determining the white blood cell count in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, selected from hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0014] In one embodiment, the method may include determining the level of hemoglobin in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples, selected from white blood cell count, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0015] In one embodiment, the method may include determining the level of serum urea nitrogen in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, these biomarkers are selected from white blood cell count, hemoglobin, serum AST, serum chloride, serum total bilirubin, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0016] In one embodiment, the method may include determining the level of serum AST in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples, selected from white blood cell count, hemoglobin, serum urea nitrogen, serum chloride, serum total bilirubin, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0017] In one embodiment, the method may include determining the level of serum chloride in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum total bilirubin, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0018] In one embodiment, the method may include determining the level of serum total bilirubin in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum globulin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0019] In one embodiment, the method may include determining the level of serum globulin in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, these biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0020] In one embodiment, the method may include determining the serum sodium level in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, these biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0021] In one embodiment, the method may include determining serum cholesterol in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0022] In one embodiment, the method may include determining the level of serum potassium in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, these biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum alkaline phosphatase, serum GGT and / or red blood cell count.
[0023] In one embodiment, the method may include determining the level of serum alkaline phosphatase in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum potassium, serum GGT and / or red blood cell count.
[0024] In one embodiment, the method may include determining the level of serum GGT in one or more samples obtained from a cat. The method may also include determining the level of one or more biomarkers in one or more samples selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum potassium, serum alkaline phosphatase and / or red blood cell count.
[0025] In one embodiment, the method may include determining the red blood cell count in one or more samples obtained from the cat. The method may also include determining the level of one or more biomarkers in one or more samples, these biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, serum cholesterol, serum potassium, serum alkaline phosphatase and / or serum GGT.
[0026] The method may include determining the level of each of white blood cell count, serum hemoglobin, serum urea nitrogen, and serum AST.
[0027] The method may include determining the level of one or more additional biomarkers in one or more samples obtained from the cat, the one or more additional biomarkers selected from hematocrit, red blood cell count, serum albumin, and / or mean corpuscular hemoglobin concentration.
[0028] In one embodiment, the method comprises determining the level of each of white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin, and mean corpuscular hemoglobin concentration.
[0029] In one embodiment, the present invention provides a method for determining the risk of mortality and / or the probability of healthy life span of a cat; the method comprising:
[0030] a. Determine the levels of the following biomarkers: white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and serum GGT in one or more samples obtained from the cat; and
[0031] b. Use formula (1) to determine the cat's phenotypic age (Phenoage):
[0032]
[0033] where xb is the sum of the values of each biomarker multiplied by their corresponding coefficients according to formula (2):
[0034]
[0035] and wherein phenotypic age is used to determine a cat's risk of mortality and / or probability of healthy lifespan.
[0036] Suitably, determining that the phenotypic age of a cat is greater than the chronological age of the cat indicates a higher risk of mortality. Suitably, determining that the phenotypic age of a cat is less than the chronological age of the cat indicates a reduced risk of mortality. Suitably, determining that the phenotypic age of a dog is greater than the chronological age of the cat indicates a reduced probability of a longer healthy lifespan. Suitably, determining that the phenotypic age of a dog is less than the chronological age of the cat indicates an increased probability of a longer healthy lifespan.
[0037] In one embodiment, the one or more samples are blood samples, such as plasma samples.
[0038] The present invention also relates to a method for selecting a lifestyle or dietary regimen for a cat, the method comprising:
[0039] a. perform the method as described in the first aspect of the present invention; and
[0040] b. Selecting a suitable lifestyle or dietary regimen based on the mortality risk and / or probability of healthy life expectancy determined in step a.
[0041] The present invention also provides a method for determining the effectiveness of a lifestyle or dietary regimen in reducing the risk of death in a cat, the method comprising: a. performing the method as described in the first aspect of the present invention; b. changing the lifestyle or dietary regimen of the cat; c. performing the method as described in the first aspect of the present invention after a period of time of changing the lifestyle or dietary regimen; and d. determining whether there is a change in the risk of death of the cat between step a and step c.
[0042] The invention also provides a dietary intervention for reducing the risk of mortality and / or the probability of healthy life span in a cat, wherein the dietary intervention is administered to a cat, wherein the risk of mortality is determined by the method of the invention.
[0043] The invention also provides for the use of a dietary intervention in reducing a determined risk of mortality and / or probability of healthy life span in a cat, wherein the dietary intervention is administered to a cat, wherein the risk of mortality and / or probability of healthy life span is determined by a method of the invention.
[0044] The present invention also provides a computer readable medium comprising instructions which, when executed, cause one or more processors to perform the method of the present invention.
[0045] The present invention also provides a computer system for determining the risk of death and / or the probability of healthy life expectancy of a cat, the computer system being programmed to perform one or more of the following steps: determining the risk of death and / or the probability of healthy life expectancy of a cat given the level of one or more biomarkers in a sample from a cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin and / or mean corpuscular hemoglobin concentration; and generating a report on the risk of death and / or the probability of healthy life expectancy of a cat.
[0046] The present invention also provides a computer program product comprising computer-implementable instructions for causing a programmable computer to determine the risk of mortality and / or probability of healthy life span for a cat given the level of one or more biomarkers from a cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin and / or mean corpuscular hemoglobin concentration.
[0047] Advantageously, embodiments of the invention in which the levels of multiple biomarkers are determined enable the determination of mortality risk and / or probability of healthy life span based on markers of multiple organ systems and functions. Thus, the use of multiple biomarkers advantageously covers a range of potential organ dysfunctions.
[0048] Assessing a cat's risk of death or probability of survival allows one to test several aspects of the animal's well-being. First, it can predict whether the animal is more likely to require a dietary or supplement-based intervention. Second, it can be used to test the efficacy of dietary or supplement-based interventions on aging. It also provides a specific set of biomarkers that can be tested to assess an animal's risk of death or probability of survival and that can be routinely tested in a veterinary clinic or office. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 - Identification of blood biomarkers predictive of mortality risk. Cox proportional hazards models were fit to each of the 28 biomarkers assessed, including sex. The p-values for each parameter were adjusted to account for multiple comparisons (by false discovery rate (FDR)). Parameters shown are those with adjusted FDR below 0.05.
[0050] Figure 2 - Demonstration that biomarkers contribute to the predictive power of a multiparameter model for determining phenotypic age. DETAILED DESCRIPTION
[0051] Various preferred features and embodiments of the present invention will now be described by way of non-limiting examples. The skilled person will appreciate that they can combine all features of the present invention disclosed herein without departing from the scope of the invention disclosed.
[0052] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0053] As used herein, the terms "comprising" and "consisting of" are synonymous with "including" or "containing" and are inclusive or open-ended and do not exclude additional unrecited members, elements, or method steps. The terms "comprising" and "consisting of" also include the term "composed of.
[0054] Numeric ranges are inclusive of the numbers defining the range.
[0055] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present patent application. Nothing herein should be construed as an admission that such publications constitute prior art to the claims appended hereto.
[0056] The methods and systems disclosed herein can be used by veterinarians, healthcare professionals, laboratory technicians, pet care providers, and the like.
[0057] Subjects
[0058] The present method is directed to a feline subject. Therefore, the subject of the present invention is a cat. Preferably, the cat is a domestic cat. More preferably, the cat is a domestic shorthair cat.
[0059] gender
[0060] Suitably, the sex of a cat may be categorized as male or female.
[0061] Chronological age
[0062] Chronological age can be defined as the amount of time that has passed from the subject's birth to a given date. Chronological age can be expressed in years, months, days, etc.
[0063] Suitably, the present methods can be applied to cats of any chronological age. In certain embodiments, the cat can be at least about 2 years old. Suitably, the cat can be at least about 2 years old, at least about 3 years old, at least about 4 years old, at least about 5 years old, at least about 6 years old, at least about 7 years old, at least about 8 years old, at least about 9 years old, or at least about 10 years old.
[0064] sample
[0065] The present invention includes the step of determining the level of one or more biomarkers in one or more samples obtained from an individual.
[0066] Preferably, the sample is derived from blood. The sample may comprise blood components or may be whole blood. The sample preferably comprises plasma and / or serum. Techniques for collecting samples from individuals are well known in the art.
[0067] The appropriate sample can be selected based on the biomarker to be determined. For example, if a complete blood count (CBC) is to be used to determine a biomarker, such as as part of a standard clinical complete blood count (CBC), a whole blood sample should be used.
[0068] The method can be performed on one or more samples obtained from a subject. For example, the method can be performed using a first sample obtained at a given time point and a second sample obtained after a time interval after the first sample is obtained. The method can be performed more than once on a sample obtained from the same cat over a period of time. For example, the sample can be obtained once a month, once a year, or once every two years. Suitably, the sample can be obtained approximately once a year (e.g., during an annual veterinary health checkup). This may help determine the effect of a specific treatment or lifestyle change, such as a dietary intervention or a change in an exercise regimen.
[0069] In one embodiment, the level of one or more biomarkers can be determined before a lifestyle change (e.g., a dietary product intervention or a change in exercise regimen). In another embodiment, the level of one or more biomarkers can be determined before and after, for example, a dietary product intervention or a change in exercise regimen. Biomarker levels can also be determined at predetermined times during, for example, the entire dietary product intervention or the change in exercise regimen. These predetermined times can be periodic, for example, every day or every three days, or can depend on the subject being tested, for example.
[0070] Determine the level of one or more biomarkers in a sample
[0071] The biomarkers used in the present invention can be determined using standard methods in the art and are typically measured as part of a standard blood test to determine the disease state of an animal. For example, biomarkers are typically determined as part of a standard clinical complete blood count (CBC) and standard clinical blood chemistry analysis.
[0072] Complete blood cell count provides information about blood cells and their properties; For example, red blood cells, white blood cells and platelets. Exemplary complete blood cell counts may include an automated process using flow cytometry or a Coulter counter to determine the number of cells in the blood. In addition to determining cell counts, such automated systems may also be able to determine other blood biomarker readings depending on their complexity. Such systems can simultaneously measure blood cell counts and red blood cell volume, hemoglobin levels, mean corpuscular hemoglobin levels and hematocrit. For example, IDEXX Laboratories provides a hematology analyzer (ProCyte Dx Hematology Analyzer of IDEXX Laboratories Inc.) that can determine white blood cell count (WBC), red blood cell count (RBC), platelet count (PLT), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH).
[0073] The levels of other biomarkers not related to blood cells, such as serum protein / enzyme and / or molecular biomarker levels, can be measured using chemical tests, particularly using automated chemical analyzer systems. These methods can be quantified using colorimetric-based methods. For example, IDEXX Laboratories provides an automated chemical analyzer (Catalyst One Chemistry Analyzer from IDEXX Laboratories Inc.) that can quantify serum albumin, serum alkaline phosphatase, serum creatine kinase, serum glucose, serum globulin, and serum calcium.
[0074] Thus, methods for determining the levels of biomarkers used in the present invention may include assays that result in spectrophotometric changes (e.g., chemical or antibody-related changes that result in a detectable signal at certain wavelengths). Such tests can be highly automated and efficient, and are the basis of many routine veterinary health examinations.
[0075] Suitably, biomarker levels may be determined after an overnight fast and measured using standard veterinary clinical practice.
[0076] The levels of individual biomarker species in a sample can be measured or determined by any suitable method known in the art. For example, mass spectrometry (MS), antibody detection methods (e.g., enzyme-linked immunosorbent assay (ELISA)), non-antibody protein scaffolds (e.g., fibronectin scaffolds), radioimmunoassays (RIA), or nucleic acid ligands can be used. Other spectrophotometric methods, chromatography, labeling techniques, or quantitative chemical methods can also be used.
[0077] Suitable antibodies for use in the above methods are known in the art and / or can be generated using known techniques. Suitable assays for detecting antibody levels include, but are not limited to, immunoassays such as enzyme-linked immunosorbent assays, radioimmunoassays, Western blotting, and immunoprecipitation.
[0078] Biomarkers
[0079] White blood cell count
[0080] Leukocytes, also known as white blood cells, are a type of cell found in the blood. They have various immune-related functions, depending on their subtype: monocytes, lymphocytes, neutrophils, basophils, and eosinophils. Leukocytes contain a nucleus and have variable cell shapes, also depending on the subtype. The white blood cell count is the number of such cells per volume of blood.
[0081] Methods for measuring white blood cell counts are known in the art and are typically expressed as thousands of cells per microliter (10^3 / uL). White blood cell count measurements can be performed manually on blood smears using staining and microscopy techniques, but can also be performed as part of an automated complete blood count (CBC). IDEXX Laboratories offers an automated hematology analyzer capable of performing white blood cell count measurements.
[0082] Suitably, an increase in white blood cell count may be associated with a negative impact on reducing the risk of death. Thus, an increase in white blood cell count may be associated with an increased risk of death.
[0083] Hemoglobin
[0084] Hemoglobin is a transport protein in red blood cells. It is composed of a tetramer of two alpha chains and two beta chains. Each peptide chain is bound to a heme group, which is composed of a porphyrin ring bound to an iron ion. This group can reversibly bind oxygen, allowing hemoglobin to be used as an oxygen transport carrier protein.
[0085] Methods for determining hemoglobin levels are well known in the art, and hemoglobin levels are usually expressed in grams per deciliter (g / dL). A standardized method for the spectrophotometric determination of hemoglobin cyanide has been described by the International Committee for Standardization in Hematology (Br J Haematol. 1967 Apr; 13: 71-5), and the method can be used in commercially available automated chemistry analyzers, such as those provided by IDEXX Laboratories.
[0086] Suitably, an increase in haemoglobin levels may be associated with a positive effect on reducing the risk of death. Thus, an increase in haemoglobin may be associated with a reduced risk of death.
[0087] Serum urea nitrogen
[0088] Urea is a waste product of the breakdown of nitrogenous compounds and is the main way nitrogen is excreted from the body. Urea is produced in the liver from ammonia, a toxic byproduct of protein metabolism. Urea circulates in the blood until it is cleared by the kidneys and excreted in the urine. Changes in the level of serum urea nitrogen (also known as blood urea nitrogen, a measure of the amount of urea in the blood) can indicate certain conditions and diseases. An overall increase in serum urea nitrogen can indicate kidney disease or hunger, while a decrease in levels can indicate chronic or severe liver disease or a low-protein diet.
[0089] Methods for determining serum urea nitrogen, which is usually expressed in milligrams per deciliter (mg / dL, natural logarithmic transformation), are well known in the art. The test commonly referred to as blood urea nitrogen (BUN) is part of a chemical test performed on serum. Generally, serum urea nitrogen can be determined by colorimetric or enzymatic conductivity methods, such as described in EP0163367 and US2006 / 0046275. The automated chemistry analyzer available from IDEXX is a commercially available system that can provide serum urea nitrogen readings.
[0090] Suitably, an increase in serum urea nitrogen may be associated with a negative impact on reducing the risk of death.Thus, an increase in serum urea nitrogen may be associated with an increased risk of death.
[0091] Serum AST
[0092] Aspartate aminotransferase AST is an enzyme involved in amino acid metabolism. AST is mainly found in the liver and muscles. Serum AST is a measure of the amount of this enzyme in the blood. High levels of AST in the blood may indicate liver or muscle damage.
[0093] Methods for determining serum AST are well known in the art, and serum AST is usually expressed in units / liter (U / L, natural logarithmic transformation). AST serum levels can be determined using colorimetric or electrochemical methods, such as those described in EP0523227 and WO2017 / 117231. The automated chemical analyzer (Catalyst One Chemistry Analyzer of IDEXX Laboratories Inc.) available from IDEXX is a commercially available system that can provide serum AST readings.
[0094] Suitably, an increase in serum AST may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum AST may be associated with an increased risk of death.
[0095] Serum chloride
[0096] Serum chloride is a measure of the concentration of chloride in the blood. Chloride is one of the most abundant electrolytes found in the blood and is very important for regulating the water content of the blood. Changes in chloride levels in the blood can indicate fluctuations in total body water content, which may be caused by conditions such as vomiting or diarrhea.
[0097] Methods for determining serum chloride are well known in the art, and serum chloride is usually expressed in millimoles per liter (mmol / L). For example, methods based on colorimetry, coulometric determination, mercury determination, and chloride ion selective electrodes (Walker HK, Hall WD, Hurst JW ed. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 197). Commercially available automated analyzers can determine serum chloride levels, such as described by Adin et al. (2020; Journal of veterinary internal medicine, 34 (1), 53–64.) or using analyzers, such as those commercially available from IDEXX laboratories.
[0098] Suitably, an increase in serum chloride levels may be associated with a positive effect on reducing the risk of death.Thus, an increase in serum chloride levels may be associated with a reduced risk of death.
[0099] Serum total bilirubin
[0100] Serum total bilirubin is a measure of the amount of bilirubin in the blood. Bilirubin is a compound produced during the decomposition of heme, which comes from hemoglobin in old or damaged red blood cells, or from the decomposition of other heme-containing proteins in other tissues, such as myoglobin. Bilirubin is processed by the liver, and the product is excreted via bile and urine. The increase in serum total bilirubin levels can indicate impaired liver or bile duct function, or indicate an increase in the level of red blood cell destruction. The increase in serum bilirubin levels can be observed by yellowing of the skin, whites of the eyes, and mucous membranes (called jaundice).
[0101] Methods for determining total serum bilirubin are generally known in the art, and total serum bilirubin is usually expressed in milligrams per deciliter (mg / dL). Bilirubin levels can be determined from blood samples via spectrophotometry, enzymatic methods, or most commonly, diazo dye colorimetric assays (described in Westwood A. (1991) The analysis of bilirubin in serum. Ann Clin Biochem 28; 119-130). Automatic analyzers are also commercially available from IDEXX for diagnostic purposes.
[0102] Suitably, an increase in total serum bilirubin may be associated with a negative impact on reducing the risk of death.Thus, an increase in total serum bilirubin may be associated with an increased risk of death.
[0103] Serum globulin
[0104] Serum globulin is a measure of the concentration of globular proteins in the blood. Globular proteins are mainly secreted by the liver, and a small portion is secreted by immune cells. The most abundant of serum globulins is albumin. The remaining serum globulins can be separated into various components based on their behavior in electrophoretic separation methods. Immunoglobulins are important components of the immune system and are secreted by immune cells. Examples of other serum globulins are immune system proteins such as complement, hormones, and carrier proteins such as ferritin. Changes in the total level of serum globulins can indicate certain conditions or diseases. An overall increase in serum globulins can indicate infection and inflammatory immune responses, while a decrease in levels can indicate bleeding, gastrointestinal disease, or severe malnutrition.
[0105] Methods for determining serum globulin levels are well known in the art, and serum globulin levels are usually expressed in grams per deciliter (g / dL). For example, chemical and physical methods are described in Tothova et al. (Veterinarni Medicina, 2016, 61: 475-496), and automated chemical analyzers obtained from IDEXX are also capable of measuring serum globulin levels.
[0106] Suitably, an increase in serum globulin levels may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum globulin levels may be associated with an increased risk of death.
[0107] Hematocrit
[0108] Hematocrit is the volume percentage of red blood cells in the blood. Hematocrit levels above normal can indicate a disease or condition that causes a higher or lower than normal proportion of red blood cells in the blood. A high hematocrit can indicate a condition such as dehydration, while a low hematocrit can indicate anemia caused by bleeding, hemolysis, or decreased red blood cell production.
[0109] Methods for determining hematocrit are well known in the art and hematocrit is usually expressed as a percentage (%) of the blood volume. It can be measured manually by centrifuging blood in a microhematocrit tube, using the packed cell volume. Alternatively, hematocrit can be calculated from the mean corpuscular volume and the red blood cell count, both of which can be measured directly in a standard complete blood count (CBC) by modern hematology analyzers.
[0110] Suitably, an increase in hematocrit level may be associated with a positive effect on reducing the risk of death. Thus, an increase in hematocrit may be associated with a reduced risk of death.
[0111] Red blood cell count
[0112] Red blood cells, also known as erythrocytes, are the most abundant cells present in the blood. These cells do not contain a nucleus, but are composed primarily of hemoglobin contained within the cell membrane to maximize their oxygen-carrying potential. Red blood cell counts that are higher or lower than normal indicate a condition or disease. A low red blood cell count may indicate hemolysis, blood loss, or decreased red blood cell production, which may be caused by a variety of reasons. A high red blood cell count may indicate a relative increase in red blood cells per volume of blood compared to normal due to dehydration or increased red blood cell production.
[0113] Methods for measuring red blood cell counts are well known in the art and are typically expressed in thousands of cells per microliter (10^3 / uL). Red blood cell count measurements can be performed manually on a blood smear using microscopy, but are typically performed as part of an automated complete blood count (CBC).
[0114] Suitably, an increase in red blood cell count may be associated with a positive effect on reducing the risk of death. Thus, an increase in red blood cell count may be associated with a reduced risk of death.
[0115] Serum albumin
[0116] Serum albumin is a globular protein found in the blood. It is a 65 kDa protein that includes three homologous domains. Albumin plays an important role in the blood, regulating osmotic pressure, preventing fluid loss from the blood to the tissues, and serving as a transport protein for fatty acids, bilirubin, heme, heavy metals, hormones, and certain drugs. Albumin is present in high levels in the blood, accounting for 25-50% by weight of total plasma protein, and is produced by the liver. Abnormally high or low levels of albumin in the blood may indicate liver or kidney disease.
[0117] Methods for measuring serum albumin levels are well known in the art, and serum albumin levels are usually expressed in grams per deciliter (g / dL); and include zone electrophoresis, dye binding assays involving bromocresol green (BCG) or bromocresol purple (BCP), and ELISA methods. For example, Eagle Biosciences provides an ELISA-based canine serum albumin assay (Eagle Biosciences Inc., product code SKU: CAE49-K01). Stokol et al. describe an automated system for using BCG binding assays in a clinical setting to determine serum albumin levels in cats (Vet Clin Pathol. 2001; 30(4): 170-176). In addition, IDEXX Laboratories provides an automated chemistry analyzer that can measure serum albumin levels as part of a combined blood test.
[0118] Suitably, an increase in serum albumin level counts may be associated with a positive effect on reducing the risk of death. Thus, an increase in serum albumin levels may be associated with a reduced risk of death.
[0119] Mean corpuscular hemoglobin concentration
[0120] Mean corpuscular hemoglobin concentration (MCHC) is the average mass of hemoglobin per given volume of packed red blood cells. MCHC values outside the normal range may indicate certain diseases, such as hypochromic anemia.
[0121] Methods for measuring MCHC are well known in the art, and MCHC is generally expressed in grams per deciliter (g / dL). Methods generally include calculations based on observed values of hemoglobin levels and hematocrit measured during a complete blood count (CBC). When a CBC is performed using a hematology analyzer as described above, MCHC is calculated using hemoglobin concentration, red blood cell count (RBC), and mean corpuscular volume (MCV).
[0122] Suitably, an increase in MCHC may be associated with a positive effect on reducing the risk of death.Thus, an increase in MCHC may be associated with a reduced risk of death.
[0123] Serum sodium
[0124] Serum sodium is a measure of the concentration of sodium in the blood. Sodium is the most abundant cation in the blood and its function is to maintain fluid distribution and osmotic pressure in the blood. Changes in serum sodium levels can indicate kidney disease or be the result of severe diarrhea or vomiting.
[0125] Methods for measuring serum sodium levels are well known in the art, and serum sodium levels are usually expressed in millimoles per liter (mmol / L). Most modern tests use direct or indirect ion-selective electrode methods. Automated analyzers capable of performing such measurements on blood samples are also commercially available, such as analyzers available from IDEXX.
[0126] Suitably, an increase in serum sodium levels may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum sodium levels may be associated with an increased risk of death.
[0127] Serum cholesterol
[0128] Serum cholesterol is a measure of the amount of cholesterol present in the blood. Cholesterol is an essential sterol that forms part of cell membranes, is involved in signal transduction, and is a metabolic precursor for a variety of steroid hormones. Cholesterol in the blood is transported via lipoproteins, which are particles containing amphipathic proteins and lipids. Changes in cholesterol levels in the blood can indicate some conditions or diseases. Low cholesterol can indicate liver disease, severe small intestinal disease, or a low-fat diet.
[0129] Methods for measuring serum cholesterol are well known in the art, and serum cholesterol is usually expressed in milligrams per deciliter (mg / dL). These include classical chemical methods such as the Abell-Kendall method, fluorogenic enzyme assays commonly used in automated systems, and mass spectrometry-based methods, all of which are discussed in Li et al. (2019; J Food Drug Anal.; 27(2): 375-386). Commercial automated analyzers capable of measuring serum cholesterol levels are available, such as those from IDEXX.
[0130] Suitably, an increase in serum cholesterol may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum cholesterol may be associated with an increased risk of death.
[0131] Serum potassium
[0132] Serum potassium is a measure of the concentration of potassium in the blood. Potassium is an important electrolyte that is found primarily within cells, and the potassium gradient across the cell's outer membrane is responsible for regulating fluid balance and generating action potentials necessary for nerve and muscle function. The proportion of potassium found in the extracellular fluid is very low, but serum concentrations can indicate certain diseases and conditions. Low serum potassium can indicate chronic kidney disease, diarrhea and vomiting, or a lack of potassium in the diet, and can lead to muscle weakness. High serum potassium can indicate kidney disease or hormonal disorders.
[0133] Methods for measuring serum potassium levels are well known in the art and are usually expressed in millimoles per liter (mmol / L). The potassium level in serum can be determined using colorimetric methods or direct or indirect ion selective electrode methods. Commercial automated analyzers capable of measuring serum potassium levels are available from IDEXX.
[0134] Suitably, an increase in serum potassium levels may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum potassium levels may be associated with an increased risk of death.
[0135] Serum alkaline phosphatase
[0136] Alkaline phosphatase (ALP) is an enzyme that plays an important role in liver metabolism and bone development. It is an 86 kDa homodimeric protein. High levels of this protein in the blood may indicate liver damage or bone disease.
[0137] Methods for measuring serum alkaline phosphatase levels are well known in the art, and serum alkaline phosphatase levels are usually expressed in units / liter (U / L, natural logarithmic transformation); and the most common method consists of quantifying enzyme activity via a colorimetric assay. Automated chemistry analyzers capable of measuring serum alkaline phosphatase levels are available from IDEXX Laboratories.
[0138] Suitably, an increase in serum alkaline phosphatase levels may be associated with a positive effect on reducing the risk of death.Thus, an increase in serum alkaline phosphatase levels may be associated with a reduced risk of death.
[0139] Serum GGT
[0140] Gamma-glutamyl transferase (GGT) is an enzyme involved in glutathione metabolism and is found primarily in the liver. Serum GGT is a measure of the amount of GGT in the blood. Increased levels of GGT in the blood may indicate liver disease, such as cholestasis.
[0141] Methods for determining serum GGT levels are well known in the art, and serum GGT levels are usually expressed in grams per deciliter (g / dL, natural logarithmic transformation). GGT levels can be determined using a colorimetric enzymatic assay, and commercial automated analyzers are available for this purpose, such as those available from IDEXX.
[0142] Suitably, an increase in serum GGT levels may be associated with a negative impact on reducing the risk of death. Thus, an increase in serum GGT levels may be associated with an increased risk of death.
[0143] Combination of biomarkers
[0144] Although a single biomarker may have predictive value in the methods of the invention, the quality and / or predictive power of the method may be improved by combining values from multiple biomarkers.
[0145] Thus, the method may involve determining the level of at least two of the biomarkers described herein. For example, the method may include determining the level of two or more biomarkers in one or more samples selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin, mean corpuscular hemoglobin concentration, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and / or serum GGT.
[0146] As used herein, the term "one or more biomarkers" may include at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or at least thirteen biomarkers.
[0147] As used herein, the term "one or more biomarkers" may include one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen biomarkers.
[0148] Suitably, the method may include determining the levels of white blood cell count, serum hemoglobin, serum urea nitrogen, and serum AST in one or more samples. Advantageously, it has been determined that this combination of four biomarkers can significantly predict the risk of death and / or the probability of healthy life span. The predictive power can be further increased by combining one or more biomarkers in the additional biomarkers, which are selected from serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin, mean corpuscular hemoglobin concentration, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and serum GGT.
[0149] Suitably, the method may comprise determining the level of each of white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and serum GGT in one or more samples.
[0150] Compare with a reference or control
[0151] The method may also include the step of comparing the levels of various biomarkers in the test sample with one or more reference or control values. The reference value may be associated with a predefined risk of death and / or probability of healthy life span. In some embodiments, the reference value is a value previously obtained for a subject or subject group with a known death outcome. The reference value may be based on the average level, such as mean or median level, from a subject group with a known chronological age, breed, sex and / or death outcome. Preferably, the reference value may be based on the average level, such as mean or median level, from a subject group with a known chronological age, breed, sex and death outcome.
[0152] Combining biomarker levels with additional measures and / or characteristics
[0153] Suitably, the method further comprises combining the level of one or more biomarkers with one or more of the chronological age and / or sex of the cat. By combining this information, an improved model for the probability of mortality risk and / or healthy life span of a cat is provided.
[0154] In a preferred embodiment, the levels of one or more biomarkers defined herein are determined in a sample from a cat and these levels are combined with the chronological age of the cat in order to determine the risk of mortality and / or probability of healthy life span for the cat.
[0155] Preferably, the risk of death and / or the probability of healthy life span is expressed as phenotypic age (Phenoage), which is given by the following formula:
[0156]
[0157] where xb is the sum of the values of each biomarker multiplied by their corresponding coefficients according to formula (2):
[0158]
[0159] as well as
[0160] c. Use phenotypic age to determine a cat’s mortality risk and / or probability of healthy lifespan.
[0161] The coefficient value of each parameter usually depends on the measurement unit of all variables in the model. As the technician will understand, the exact value of each coefficient value will therefore depend on the quantity and property of the different parameters used in the model and the nature of the training data provided (for example, the breed of the cat in the training data set). Therefore, conventional statistical methods can be applied to the training data set to obtain the coefficient value for the above formula. This method includes, for example, calculating two gompertz functions (for example, in the case of the state (survival or death) of a known cat) on the training set, a function models the survival rate as a function (model 1) of selected biomarkers, chronological age and sex, and a second function only considers chronological age and sex (model 2). These models can be fitted using flexsurv package (v 2.1) in the R software environment.
[0162] Suitably, a negative coefficient for a given biomarker means that a higher level of the biomarker has a positive effect on reducing the risk of death, and / or a lower level of the biomarker has a negative effect on reducing the risk of death. Suitably, a positive coefficient for a given biomarker means that a higher level of the biomarker has a negative effect on reducing the risk of death, and / or a lower level of the biomarker has a positive effect on reducing the risk of death.
[0163] Phenotypic age can be defined as the time variable ("chronological age") at which the probability of survival of an animal given by Model 2 is equal to the probability of survival given by Model 1 at their chronological age.
[0164] The phenotypic age of a cat can be expressed in years, months, days, etc.
[0165] Preferably, the risk of death and / or the probability of healthy life span is expressed as the difference between the phenotypic age and the chronological age of the cat. This difference can be referred to as the phenotypic age advance of the cat.
[0166] For example, an increase in phenotypic age compared to chronological age may indicate an increased risk of death for a cat. For example, a decrease in phenotypic age compared to chronological age may indicate a decreased risk of death for a cat. As an illustration, the inventors determined that a difference between phenotypic age and chronological age (an advance in phenotypic age) was associated with a significant increase in the risk of death, and the magnitude of the effect was calculated as: the hazard ratio for an increase of 1 year in phenotypic age compared to chronological age was 1.36 (see Example 3). In other words, the inventors determined that an increase of 1 year in phenotypic age compared to chronological age was associated with an approximately 35% increase in the risk of death at any given point in life.
[0167] Individual classification
[0168] The probability of the risk of death and / or healthy life span determined by the method of the present invention can also be compared with one or more predetermined threshold values. Using this threshold value, the subject can be stratified into each category indicating the probability of the risk of death (e.g., low, medium or high determined risk of death) and / or healthy life span determined. The divergence degree with the threshold value can be used to determine which individuals will benefit most from certain interventions. In this way, dietary intervention and lifestyle changes can be optimized. The probability of the determined risk of death and / or healthy life span can be expressed with a numerical score or percentage, for example, it can indicate the probability of the determined risk of death and / or healthy life span compared with a control or reference group.
[0169] Method for selecting / monitoring a subject's lifestyle or dietary regimen
[0170] In another aspect, the invention provides a method for selecting a lifestyle or dietary regimen for a subject. The change in lifestyle can be any change described herein, such as a change in dietary intervention and / or an exercise regimen. The change in lifestyle can be the administration of a therapeutic approach.
[0171] Lifestyle or dietary regimen can be applied to cats in any suitable time period. After the period of time, the method can be used to determine the risk of death and / or the probability of healthy life span of cats again, so as to determine the efficacy of lifestyle or dietary regimen to reduce the risk of death and / or increase the probability of healthy life span of cats. For example, lifestyle or dietary regimen can be applied for at least 2 weeks, at least 4 weeks, at least 8 weeks, at least 16 weeks, at least 32 weeks or at least 64 weeks. Lifestyle or dietary regimen can be applied for at least 3 months, at least 6 months, at least 12 months, at least 24 months, at least 36 months, at least 48 months or at least 60 months.
[0172] Preferably, the change is a dietary intervention as described herein. The term "dietary intervention" refers to an external factor that is applied to a subject and causes a change in the subject's diet. More preferably, the dietary intervention comprises the administration of at least one dietary product or dietary regimen or nutritional supplement.
[0173] Dietary interventions can be meals, meal regimens, supplements, or supplement regimens.
[0174] The dietary intervention or dietary product described herein can be any suitable dietary regimen, such as a calorie-restricted diet, an elderly diet, a low-protein diet, a phosphorus diet, a low-protein diet, a potassium-supplemented diet, a polyunsaturated fatty acid (PUFA)-supplemented diet, an antioxidant-supplemented diet, a vitamin B-supplemented diet, a liquid diet, a selenium-supplemented diet, an ω3-6 ratio diet, or a diet supplemented with carnitine, branched-chain amino acids or derivatives, nucleotides, nicotinamide precursors (such as nicotinamide mononucleotide (MNM) or nicotinamide riboside (NR)), or any combination of the foregoing.
[0175] Suitably, the dietary intervention or dietary product may be a calorie restricted diet, an elderly diet or a low protein diet. Suitably, the dietary intervention or dietary product may be a calorie restricted diet. Suitably, the dietary intervention or dietary product may be a low protein diet.
[0176] The dietary intervention may be determined based on the cat's baseline maintenance energy requirement (MER). Suitably, the MER may be the amount of food that stabilizes the cat's body weight (varies by less than 5% over three weeks).
[0177] For example, it is generally believed that young, growing cats benefit from a high-energy / high-protein diet; however, older cats may have lower energy requirements, so the diet may be adjusted appropriately. In particular, many manufacturers produce "senior" lines of cat foods that are lower in calories and higher in fiber, but with protein and fat levels appropriate for older cats.
[0178] Suitably, the calorie restricted diet may comprise about 60%, about 65%, about 75% or about 80% of the feline MER. Suitably, the calorie restricted diet may comprise about 60% or about 75% of the feline MER.
[0179] Suitably, the low protein diet may comprise less than 20% protein (dry matter %).For example, the low protein diet may comprise less than 15% or less than 10% protein (dry matter %).
[0180] These diets are typically recommended based on the cat's chronological age. For example, it may be recommended that a cat be switched to a senior diet around 7 or 8 years old. However, in the context of the present invention, determining that a cat has an increased risk of mortality and / or a decreased probability of healthy life span than would be expected given its chronological age may allow for a determination to switch a cat to a senior diet at an earlier age. In contrast, a cat with a decreased risk of mortality and / or an increased probability of healthy life span compared to its chronological age may be able to continue to enjoy a high energy / high protein diet for longer.
[0181] The dietary intervention may include foods, supplements and / or beverages that contain nutrients and / or bioactive agents that mimic the benefits of caloric restriction (CR) without limiting daily caloric intake. For example, foods, supplements and / or beverages may contain functional ingredients with benefits similar to CR. Suitably, foods, supplements and / or beverages may contain autophagy inducers. Suitably, foods, supplements and / or beverages may contain fruits and / or nuts. Suitable examples include, but are not limited to, pomegranates, strawberries, blackberries, camu camu, walnuts, chestnuts, pistachios, pecans. Suitably, foods, supplements and / or beverages may contain probiotics, with or without fruit extracts or nut extracts.
[0182] Modifying the subject's lifestyle also includes indicating that the subject needs to change his lifestyle, such as prescribing more exercise. Similar to dietary intervention, determining that the cat has an increased risk of mortality and / or a decreased probability of healthy lifespan compared to what would be expected given its chronological age can allow for the determination of switching the cat to an appropriate exercise regimen.
[0183] The lifestyle of changing the experimenter also comprises recommending treatment mode or scheme.Treatment mode or scheme can be the mode for treating and / or preventing for example arthritis, dental disease, endocrine disease, heart disease, diabetes, hepatopathy, nephropathy, prostate disease, cancer and behavior or cognitive disorder.Suitably, can be to be identified as being in this disease risk due to the specific biomarker of death risk (phenotype age) increase and / or based on known disease-related pathways being associated and apply preventive treatment to the cat.In other embodiments, can be more regularly monitored and be determined as being in the risk of some symptom cat (due to the specific biomarker of death risk (phenotype age) increase and / or based on known disease-related pathways being associated), so that can start diagnosis and treatment as early as possible.
[0184] Thus, the present invention can advantageously enable the identification of cats that are expected to respond particularly well to a given intervention (e.g., a lifestyle or dietary regimen). Thus, the intervention can be applied in a more targeted manner to cats that are expected to respond.
[0185] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span of a cat, the method comprising:
[0186] a. Determine the first mortality risk and / or health life expectancy of a cat according to the method of the first aspect of the present invention;
[0187] b. Applying a lifestyle or dietary regimen to a cat;
[0188] c. determining the probability of a second mortality risk and / or healthy life span of the cat according to the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0189] d. Determine whether there is a change between the first risk of mortality and / or probability of healthy life span and the second risk of mortality and / or probability of healthy life span for the cat after a period of following the lifestyle or dietary regimen.
[0190] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality determined for a cat and / or increasing the probability of a healthy life span determined for a cat, the method comprising:
[0191] a. applying a lifestyle or dietary regimen to a cat, wherein the lifestyle or dietary regimen has been selected according to a method comprising performing the method according to the first aspect of the invention; and selecting an appropriate lifestyle or dietary regimen based on the determined risk of death and / or probability of healthy life span;
[0192] b. determining the probability of a second mortality risk and / or healthy life span of a cat by performing the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0193] c. Determine whether there is a change in the risk of mortality and / or probability of healthy life span in a cat after a period of following the lifestyle or dietary regimen.
[0194] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span of a cat, the method comprising:
[0195] a. Selecting a lifestyle or dietary regimen for a cat according to a method, the method comprising performing the method according to the first aspect of the present invention; and based on the determined risk of death, selecting an appropriate lifestyle or dietary regimen;
[0196] b. Applying a lifestyle or dietary regimen to a cat;
[0197] c. determining the probability of a second mortality risk and / or healthy life span of the cat according to the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0198] d. Determine whether the cat's risk of mortality and / or probability of healthy life span has changed between step a and step c.
[0199] After a period of administration of the lifestyle or dietary regimen, a reduction in the second (or subsequent) risk of death determined for a cat compared to the first (or earlier) risk of death and / or the probability of healthy lifespan determined for the cat indicates that the lifestyle or dietary regimen is effective in reducing the risk of death and / or the probability of healthy lifespan for the cat.
[0200] The probability of the risk of death and / or healthy life span of a cat can be determined before and after the lifestyle or dietary regimen is applied to a cat. The probability of the risk of death and / or healthy life span of a cat can also be determined at the scheduled time during the application of the whole lifestyle or dietary regimen. These scheduled times can be periodic during the whole lifestyle or dietary regimen, such as every day or every three days, every week, every two weeks, every month, every two months, every 6 months, every year or every two years. The scheduled time can depend on the subject being tested. Suitably, before determining the first risk of death, a lifestyle or dietary regimen may have been applied to a cat for a period of time; However, the effectiveness of the lifestyle or dietary regimen to reduce the risk of death can still be monitored by determining the risk of death at two or more scheduled times during the application of the lifestyle or dietary regimen.
[0201] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span of a cat, the method comprising:
[0202] a. Determine the first mortality risk and / or health life expectancy of a cat according to the method of the first aspect of the present invention;
[0203] b. Applying a lifestyle or dietary regimen to a cat;
[0204] c. determining the probability of a second mortality risk and / or healthy life span of the cat according to the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0205] d. Determine whether there is a change between the first risk of mortality and / or probability of healthy life span and the second risk of mortality and / or probability of healthy life span for the cat after a period of following the lifestyle or dietary regimen.
[0206] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality determined for a cat and / or increasing the probability of a healthy life span determined for a cat, the method comprising:
[0207] a. applying a lifestyle or dietary regimen to a cat, wherein the lifestyle or dietary regimen has been selected according to a method comprising performing a method according to the first aspect of the present invention; and based on the determined risk of mortality, selecting an appropriate lifestyle or dietary regimen;
[0208] b. determining the probability of a second mortality risk and / or healthy life span of a cat by performing the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0209] c. Determine whether there is a change in the risk of mortality and / or probability of healthy life span in a cat after a period of following the lifestyle or dietary regimen.
[0210] The present invention also provides a method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span of a cat, the method comprising:
[0211] a. Selecting a lifestyle or dietary regimen for a cat according to a method, the method comprising performing the method according to the first aspect of the present invention; and based on the determined risk of death, selecting an appropriate lifestyle or dietary regimen;
[0212] b. Administering a lifestyle or dietary regimen to a cat;
[0213] c. determining the probability of a second mortality risk and / or healthy life span of the cat according to the method of the first aspect of the present invention after the lifestyle or dietary regimen has been applied to the cat for a period of time;
[0214] d. Determine whether the cat's risk of mortality has changed between step a and step c.
[0215] After a period of administration of the lifestyle or dietary regimen, a reduction in the second (or subsequent) risk of death determined for the cat compared to the first (or earlier) risk of death determined for the cat indicates that the lifestyle or dietary regimen is effective in reducing the cat's risk of death.
[0216] The probability of the risk of death and / or healthy life span of a cat can be determined before and after the lifestyle or dietary regimen is applied to a cat. The probability of the risk of death and / or healthy life span of a cat can also be determined at the scheduled time during the application of the whole lifestyle or dietary regimen. These scheduled times can be periodic during the whole lifestyle or dietary regimen, such as every day or every three days, every week, every two weeks, every month, every two months, every 6 months, every year or every two years. The scheduled time can depend on the subject being tested. Suitably, before determining the probability of the first risk of death and / or healthy life span, a lifestyle or dietary regimen may have been applied to a cat for a period of time; However, the effectiveness of the lifestyle or dietary regimen to reduce the probability of the risk of death and / or healthy life span can still be monitored by determining the probability of the risk of death and / or healthy life span at two or more scheduled times during the application of the lifestyle or dietary regimen.
[0217] Uses of dietary intervention
[0218] In one aspect, the invention provides a dietary intervention for reducing the risk of mortality and / or increasing the probability of a healthy lifespan in a cat, wherein the dietary intervention is administered to a cat, wherein the risk of mortality and / or the probability of a healthy lifespan is determined by the present method.
[0219] In another aspect, the present invention provides the use of a dietary intervention in reducing the predicted risk of mortality and / or increasing the probability of healthy lifespan of a cat, wherein the dietary intervention is administered to a cat, wherein the risk of mortality and / or the probability of healthy lifespan is determined by the present method.
[0220] As described herein, a dietary intervention can be a dietary product or dietary regimen or a nutritional supplement.
[0221] Computer program product
[0222] The method can be performed using a computer. Therefore, the method can be performed on a computer.
[0223] The methods described herein can be implemented as computer programs running on general-purpose hardware such as one or more computer processors. In some embodiments, the functions described herein can be implemented by devices such as smart phones, tablet terminals or personal computers.
[0224] In one aspect, the present invention provides a computer program product comprising computer-implementable instructions for causing a programmable computer to determine the risk of mortality and / or probability of healthy life span for a cat as described herein.
[0225] In another aspect, the invention provides a computer program product comprising computer-implemented instructions for causing a device to determine a cat's risk of death and / or probability of healthy life span given a level of one or more biomarkers from a user, wherein the biomarker is selected from one or more biomarkers as defined herein. Preferably, the biomarker level is a fasting level. Additional parameters or characteristics of a cat may also be provided to the computer program product. As described herein, additional parameters or characteristics may include chronological age, breed, and gender.
[0226] In one embodiment, the user inputs the level of one or more of the biomarkers as defined herein into the device, optionally along with chronological age, breed and sex. The device then processes this information and provides a determination of the probability of mortality risk and / or healthy life span for the cat.
[0227] The device can generally be a server on a network. However, any device can be used as long as it can process biomarker data and / or additional parameters or characteristics using a processor, a central processing unit (CPU), etc. The device can be, for example, a smart phone, a tablet terminal, or a personal computer, and outputs information indicating the determined risk of death and / or the probability of healthy life span of a cat. The determined risk of death and / or the probability of healthy life span can be represented by a numerical score or percentage, for example, it can indicate the determined risk of death and / or the probability of healthy life span compared to a control or reference population.
[0228] Those skilled in the art will understand that they can freely combine all features of the present invention described herein without departing from the scope of the invention disclosed herein.
[0229] Example
[0230] The present invention will now be further described by way of examples, which are intended to help those skilled in the art to practice the present invention but are not intended to limit the scope of the present invention in any way.
[0231] Example 1 - Determination of blood biomarkers associated with mortality risk in cats
[0232] Predictive blood biomarkers were determined from a biomarker panel consisting of a standard clinical complete blood count (CBC) and standard clinical blood chemistry analysis. Serum samples were collected after an overnight fast and measured using standard veterinary clinical practice.
[0233] Table 1 - Clinical complete blood count (CBC) and clinical blood chemistry analysis
[0234]
[0235]
[0236] *Values were log-transformed using the natural logarithm.
[0237] We conducted a longitudinal study of cats with repeated measures on these parameters as well as on the cats’ status (alive or dead) and sex. Analyses were for domestic shorthair breeds. We then organized the data using the R programming language. For each cat, we recorded the biomarkers as time-dependent covariates using a time interval open on the left and closed on the right (i.e., (tstart, tstop)), where the biomarker information corresponded to the start of the interval and the event (alive or dead) was recorded as the last tstop value. To do this, we used the tmerge function of the survival package in R (v.3.2--13). We then fit a Cox proportional hazards model to the data separately for each of the 28 biomarkers and sex as covariates. We then adjusted the p-value for each parameter to account for multiple comparisons (by the false discovery rate (FDR)), and selected features with an adjusted FDR below 0.05 ( Figure 1 ).
[0238] Using this approach, we identified 11 biomarkers that individually predicted a cat’s probability of survival:
[0239] Hemoglobin (g / dL)
[0240] White blood cell count (10^3 / ul)
[0241] Hematocrit (%)
[0242] Red blood cell count (10^3 / ul)
[0243] Serum urea nitrogen (mg / dL, natural logarithmic transformation)
[0244] Serum AST (U / L, natural logarithm transformation)
[0245] Serum chloride (mmol / L)
[0246] Serum total bilirubin (mg / dL)
[0247] Serum globulin (g / dL)
[0248] Serum albumin (g / dL)
[0249] Mean corpuscular hemoglobin concentration (g / dL)
[0250] Example 2 - Multi-parameter model for predicting mortality risk
[0251] Next, we constructed the best model that considered multiple parameters simultaneously, as this is more likely to cover the various organ dysfunctions that occur with aging. However, selecting several features that may be correlated with each other will be biased. To avoid this problem, we used a penalized regression approach using the glmnet package (v4.1-3). We fit a LASSO penalized cox proportional hazards model to the data, and used 20-fold cross-validation to compare different values of the penalty parameter λ. This approach selected the 13 blood biomarkers that were most predictive of survival, ranked in order of importance as follows:
[0252] White blood cell count (10^3 / ul)
[0253] Hemoglobin (g / dL)
[0254] Serum urea nitrogen (mg / dL, natural logarithmic transformation)
[0255] Serum AST (U / L, natural logarithm transformation)
[0256] Serum chloride (mmol / L)
[0257] Serum total bilirubin (mg / dL)
[0258] Serum globulin (g / dL)
[0259] Serum sodium (mmol / L)
[0260] Serum cholesterol (mg / dL)
[0261] Serum potassium (mmol / L)
[0262] Serum alkaline phosphatase (U / L)
[0263] Serum GGT (g / dL)
[0264] Red blood cell count (10^3 / ul)
[0265] To extract the phenotypic age of the animals, we calculated two different gompertz functions on our training set, one that models survival as a function of the selected biomarkers and age (model 1), while the second one takes into account age only (model 2). These models were fitted using the flexsurv package (v 2.1). Phenotypic age was defined as the time variable ('age') under which the probability of survival of the animals given by model 2 was equal to the probability of survival given by model 1 at their chronological age. This resulted in a mathematical function linking blood biomarkers to phenotypic age and is given by the following formula:
[0266]
[0267] where xb is the sum of the values of each biomarker multiplied by their corresponding coefficients. The coefficients are given by two gompertz functions trained on our training set.
[0268] As an example, the coefficients as well as γ and γ2 values have been measured for the full list of biomarkers from our training set and are given in Table 1.
[0269]
[0270] Table 2 - Coefficients and gamma values have been measured from the training set
[0271] coefficient γ 0.1968988 <![CDATA[β0]]> -2.943895 Beta cell count 0.03858239 Beta hemoglobin -0.1590607 Beta cell count -0.1234486 Beta serum cholesterol 0.002024294 Beta serum potassium 0.1692257 Beta serum chloride -0.08637897 Beta serum sodium 0.04714968 beta serum urea nitrogen 0.3992681 Serum total bilirubin 2.867167 β serum AST 0.4198243 Serum alkaline phosphatase β -0.3322447 Beta serum globulin 0.1615517 β serum GGT 0.07676414 <![CDATA[γ2]]> 0.2937868 <![CDATA[β 02 ]]> -5.7844426
[0272] Furthermore, we observed a decrease in the strength of survival prediction by reducing the set of 13 biomarkers by systematically removing one biomarker from the top of the list (p-value). The decrease was most pronounced for the first four parameters, confirming their largest contribution, but we observed changes in the quality of predictions each time the set was reduced, indicating that each parameter contributes to the overall prediction ( Figure 2 ).
[0273] Example 3 - Using phenotypic age to predict mortality risk
[0274] It was subsequently demonstrated that when the resulting phenotypic ages were applied to a test set consisting only of cats not used during algorithm training, the discrepancy between phenotypic age and chronological age (advanced phenotypic age) was associated with a significantly increased risk of mortality.
[0275] The effect size was calculated as a hazard ratio of 1.36 for each 1-year increase in phenotypic age compared with chronological age.
[0276] All publications mentioned in the above description are incorporated herein by reference. Various modifications and variations of the methods, compositions and uses disclosed in the present invention will be apparent to the skilled person without departing from the scope and spirit of the present invention. Although the present invention has been disclosed in conjunction with specific preferred embodiments, it should be understood that the present invention protected by the claims should not be unduly limited to such specific embodiments. In fact, various modifications to the modes disclosed for practicing the present invention that are apparent to the skilled person are intended to fall within the scope of the following claims.
Claims
1. A method for determining the risk of mortality and / or the probability of healthy life span of a cat; the method comprising determining the level of one or more biomarkers in one or more samples obtained from the cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, hematocrit, red blood cell count, serum albumin and / or mean corpuscular hemoglobin concentration.
2. A method for determining the risk of mortality and / or the probability of healthy life span of a cat; the method comprising determining the level of one or more biomarkers in one or more samples obtained from the cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin and / or red blood cell count.
3. The method of claim 1 or 2, wherein the biomarker is white blood cell count.
4. The method according to any preceding claim, wherein the biomarker is hemoglobin.
5. The method according to any preceding claim, wherein the biomarker is serum urea nitrogen.
6. The method according to any preceding claim, wherein the biomarker is serum AST.
7. The method according to any preceding claim, wherein the method comprises determining the level of each of white blood cell count, serum hemoglobin, serum urea nitrogen and serum AST.
8. A method according to any preceding claim; wherein the level of one or more additional biomarkers is determined in the one or more samples obtained from the cat, the one or more additional biomarkers being selected from serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and / or serum GGT.
9. The method according to any one of claims 2 to 8, wherein the method comprises determining the level of each of white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and serum GGT.
10. The method according to any preceding claim, wherein the one or more samples are blood samples.
11. The method of any preceding claim, wherein the method further comprises combining the levels of the one or more biomarkers with the chronological age of the cat.
12. A method for determining the risk of mortality and / or the probability of healthy life span of a cat; the method comprising: a. determining the levels of the following biomarkers: white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and serum GGT in one or more samples obtained from the cat; and b. Use formula (1) to determine the cat's phenotypic age (Phenoage): where xb is the sum of the values of each biomarker multiplied by their corresponding coefficients according to formula (2): as well as c. Using the phenotypic age to determine the cat's risk of mortality and / or probability of healthy life span.
13. The method of claim 12, wherein determining that the phenotypic age of the cat is greater than the chronological age of the cat indicates a higher risk of mortality and / or a decreased probability of healthy lifespan.
14. The method of claim 12, wherein determining that the phenotypic age of the cat is less than the chronological age of the cat indicates a lower risk of mortality and / or an increased probability of healthy lifespan.
15. A method according to any preceding claim, wherein the method is performed on one or more samples obtained before and after a time interval and it is determined whether the risk of mortality and / or probability of healthy life span of the cat has changed during the time interval.
16. A method for assessing the aging rate of a cat, the method comprising performing the method according to any one of claims 12 to 15; wherein (i) determining that the phenotypic age of the cat is greater than the actual age of the cat indicates a faster aging rate, or (ii) determining that the phenotypic age of the cat is less than the actual age of the cat indicates a slower aging rate.
17. A method for selecting a lifestyle or dietary regimen for a cat, the method comprising: a. Execute the method as claimed in any one of claims 1 to 15; as well as b. Selecting a suitable lifestyle or dietary regimen based on the mortality risk and / or probability of healthy life expectancy determined in step a.
18. The method of claim 17, wherein the lifestyle or dietary regimen is a dietary intervention.
19. The method according to claim 17 or 18, wherein the dietary intervention is a calorie-restricted diet, an elderly diet or a low-protein diet; preferably a calorie-restricted diet.
20. A method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span in a cat, the method comprising: a. Determine the first mortality risk and / or the probability of healthy life span of the cat according to the method described in any one of claims 1 to 15; b. administering a lifestyle or dietary regimen to the cat; c. after the lifestyle or dietary regimen has been administered to the cat for a period of time, Determining the second mortality risk and / or the probability of healthy life span of the cat according to the method of any one of claims 1 to 15; d. Determining whether there is a difference between the first risk of mortality and / or probability of healthy life span and the second risk of mortality and / or probability of healthy life span for the cat after following the lifestyle or dietary regimen for the time period.
21. A method for determining the efficacy of a lifestyle or dietary regimen for reducing the risk of mortality determined for a cat and / or increasing the probability of a healthy life span determined for a cat, the method comprising: a. applying a lifestyle or dietary regimen to the cat, wherein the lifestyle or dietary regimen has been selected according to the method of any one of claims 17 to 19; b. after applying the lifestyle or dietary regimen to the cat for a period of time, performing the method according to any one of claims 1 to 15; c. Determining whether there is a change in the risk of mortality and / or probability of healthy life span of the cat after following the lifestyle or dietary regimen for the period of time.
22. A method for determining the efficacy of a lifestyle or dietary regimen in reducing the risk of mortality and / or increasing the probability of a healthy life span in a cat, the method comprising: a. Selecting a lifestyle or dietary regimen for the cat according to the method according to any one of claims 17 to 19; b. administering the lifestyle or dietary regimen to the cat; c. after the lifestyle or dietary regimen has been administered to the cat for a period of time, Determining the second mortality risk and / or the probability of healthy life span of the cat according to the method of any one of claims 1 to 15; d. Determining whether the risk of mortality and / or probability of healthy life span of the cat has changed between step a and step c.
23. The method according to any one of claims 20 to 22, comprising further changing the lifestyle or dietary regimen to reduce the risk of death of the cat and / or increase the probability of the healthy life span of the cat.
24. A method of determining the likelihood that a cat will benefit from a lifestyle or dietary regimen; the method comprising: a. Determine the risk of death and / or probability of healthy life span of the cat according to the method described in any one of claims 1 to 15; b. Identify a cat as likely to respond to the lifestyle or dietary regimen if the cat has an increased risk of mortality and / or a decreased probability of healthy lifespan compared to the cat's chronological age.
25. A method for selecting a cat suitable for receiving a lifestyle or dietary regimen; the method comprising: a) determining the risk of death and / or the probability of healthy life span of the cat according to the method of any one of claims 1 to 15; b) Selecting a cat as suitable for receiving a lifestyle or dietary regimen if the cat has an increased risk of mortality and / or a decreased probability of healthy lifespan compared to the cat's chronological age.
26. A method for reducing the risk of mortality and / or increasing the probability of a cat's healthy life span; the method comprising: a. determining the risk of death and / or probability of healthy life span of the cat; the method comprising determining the level of one or more biomarkers in one or more samples obtained from the cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, serum GGT and / or red blood cell count; b. selecting an appropriate lifestyle or dietary regimen based on the mortality risk and / or health life expectancy probability determined in step a; c. administering the selected lifestyle or dietary regimen to the cat.
27. The method of claim 26, wherein step a comprises the method of any one of claims 1 to 15.
28. A method for reducing the risk of mortality and / or the probability of healthy life span in a cat, the method comprising administering a dietary intervention to a cat identified as being in need of the dietary intervention by the method of any one of claims 1 to 15.
29. A dietary intervention for reducing the risk of death and / or increasing the probability of a healthy life span in a cat, wherein the dietary intervention is administered to a cat, wherein the risk of death and / or the probability of a healthy life span is determined by a method according to any one of claims 1 to 15.
30. Use of a dietary intervention to reduce the risk of mortality and / or increase the probability of a healthy life span in a cat, wherein the dietary intervention is administered to a cat, wherein the risk of mortality and / or the probability of a healthy life span is determined by a method according to any one of claims 1 to 15.
31. The method, dietary intervention for use or use according to any one of claims 26 to 30, wherein the dietary intervention is a calorie restricted diet, an elderly diet or a low protein diet; A calorie restricted diet is preferred.
32. A computer readable medium comprising instructions which, when executed, cause one or more processors to perform the method of any one of claims 1 to 15.
33. A computer system for determining the risk of mortality of a cat, the computer system being programmed to perform one or more of the following steps: determining the risk of mortality and / or the probability of healthy lifespan for a cat given the level of one or more biomarkers in a sample from a cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and / or serum GGT, and generating a report of the risk of mortality and / or probability of healthy life span for the cat.
34. A computer program product comprising computer-implementable instructions for causing a programmable computer to determine the risk of mortality and / or probability of healthy life span for a cat given the level of one or more biomarkers from the cat, wherein the one or more biomarkers are selected from white blood cell count, hemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase and / or serum GGT.
35. The computer system or computer program product of any one of claims 33 to 34, wherein the biomarker is white blood cell count.
36. The computer system or computer program product of any one of claims 33 to 35, wherein the biomarker is hemoglobin.
37. The computer system or computer program product of any one of claims 33 to 36, wherein the biomarker is serum urea nitrogen.
38. The computer system or computer program product of any one of claims 33 to 37, wherein the biomarker is serum AST.
